Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q7Z403
UPID:
TMC6_HUMAN
Alternative names:
Epidermodysplasia verruciformis protein 1; Protein LAK-4
Alternative UPACC:
Q7Z403; O43284; Q45VJ2; Q8IU98; Q8IUI7; Q8IWU8; Q8TEQ7; Q9HAG5
Background:
Transmembrane channel-like protein 6, also known as Epidermodysplasia verruciformis protein 1 or Protein LAK-4, plays a crucial role as a probable ion channel. This protein's involvement in cellular processes underscores its significance in maintaining cellular homeostasis and signaling.
Therapeutic significance:
Linked to Epidermodysplasia verruciformis 1, a condition with a high risk of skin carcinoma due to susceptibility to specific human papillomaviruses, understanding the role of Transmembrane channel-like protein 6 could open doors to potential therapeutic strategies. Targeting this protein may offer novel approaches for treating or managing this genodermatosis.